Adam Whaley-Connell, DO
Nephrology · Columbia, MONPI 1447204045
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,100 of the $2,617 with a category attached, or 80.2%. Vifor Pharma, Inc. accounts for 82.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2021 at $2,100 and has fallen 90.2% since, to $206 in 2025.
Across 23 payments — averaging $113.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$2K
- Amgen$77
- Otsuka America Pharmaceutical, Inc.$68
- Vantive US Healthcare LLC$59
- Mallinckrodt Hospital Products Inc.$50
- Akebia Therapeutics Inc$38
- plus $171 from 7 others
Across 68 payments — averaging $2798.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$165K
- Gilead$19K
- AbbVie$7K
What the payments were for
- Speaking & faculty fees$2,10080%
- Food & beverage$51720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 5 | $2,155 |
| Amgen(2 entities) | 3 | $77 |
| Otsuka America Pharmaceutical, Inc. | 1 | $68 |
| Vantive US Healthcare LLC | 1 | $59 |
| Mallinckrodt Hospital Products Inc. | 3 | $50 |
| Akebia Therapeutics Inc | 2 | $38 |
| Baxter Healthcare | 2 | $32 |
| Travere Therapeutics, Inc. | 1 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Sanofi | 1 | $25 |
| Mozarc Medical US LLC | 1 | $23 |
| GSK | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
How this compares
$2,617 in reported general payments places this provider in the 70th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Columbia
- Zbylut TwardowskiColumbia$43K
- Kunal ChaudharyColumbia$36K
- Preethi YerramColumbia$35K
- John VanstoneColumbia$28K
- Ramesh KhannaColumbia$14K
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Kevin MartinSt Louis$189K
- Alejandro AlvarezFlorissant$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.